Searchable abstracts of presentations at key conferences in endocrinology

ea0063gp172 | Obesity (1) | ECE2019

Pituitary surgery as first-line therapy for microprolactinomas

Teulade Marie , Lasolle Helene , Vasiljevic Alexandre , Borson-Chazot Francoise , Jouanneau Emmanuel , Raverot Gerald

Introduction: Dopamine agonists (DA), reference treatment for microprolactinomas, rarely allow long term remission. The performance of endoscopic pituitary surgery should be examined as first-line treatment.Objective: To evaluate the remission rate of microprolactinoma operated by endoscopic transphenoidal approachMethods: We retrospectively studied the surgical results of the 35 microprolactinomas operated between 2010 to 2017 in ...

ea0041oc13.4 | Pituitary Clinical | ECE2016

Diagnosis and management of thyrotropin-secreting pituitary tumors: a single center experience with a long-term follow-up of 30 patients

Capraru Oana-Maria , Gaillard Celine , Vasiljevic Alexandre , Raverot Veronique , Borson-Chazot Francoise , Jouanneau Emmanuel , Raverot Gerald

TSH secreting pituitary adenomas are rare tumours for which the treatment of choice is neurosurgery but in some cases medical treatment with somatostatin analogs (SSA) can lead to a good control of symptoms and shrinkage of the tumour.The objective of this study was to review 30 patients diagnosed with TSH-omas between October 1981–July 2014, followed-up for a median of 43.93 months (1.12–192.11) in our University Hospital from Lyon, France.</p...

ea0041ep862 | Pituitary - Basic | ECE2016

The silent somatotroph tumours

Chinezu Laura , Vasiljevic Alexandre , Lapoirie Marion , Trouillas Jacqueline , Jouanneau Emmanuel , Raverot Gerald

Introduction: Silent somatotroph tumours are GH immunoreactive (IR) pituitary tumours without clinical and biological signs of acromegaly. In our series, they represent 16% of all the somatotroph pituitary tumours. The aim of our study was to compare the somatotroph tumours with and without acromegaly to a better characterization of these silent tumours.Materials and methods: Fifty-nine tumours with acromegaly and 21 silent somatotroph tumours were studi...

ea0041ep880 | Pituitary - Clinical | ECE2016

Predictive factors of surgical outcomes in acromegaly: what’s new in 2016?

Lapoirie Marion , Vasiljevic Alexandre , Rabilloud Muriel , Lapras Veronique , Chinezu Laura , Trouillas Jacqueline , Jouanneau Emmanuel , Raverot Gerald

Introduction: In the era of personalized patient management in acromegaly, transsphenoidal surgery remains a treatment of choice in cases where surgical cure can be expected. In order to better target these patients and to assess the risk of persistence/progression disease, we evaluated clinical, hormonal, radiological and pathological predictors of surgical outcome in acromegaly.Methods: A single-institution retrospective study from 2009 to 2015 was per...

ea0070aep674 | Pituitary and Neuroendocrinology | ECE2020

A key role for conservative treatment in the management of pituitary apoplexy

Marx Claire , Rabilloud Muriel , Borson-Chazot Francoise , Tilikete Caroline , Jouanneau Emmanuel , Raverot Gerald

Objective: The management of pituitary apoplexy, a rare emergency neuroendocrine condition, is controversial. The aim of the present study was to compare the outcome of patients with pituitary apoplexy managed either by a conservative or surgical approach.Methods: A retrospective cohort study including patients diagnosed between 2007 and 2018 in a tertiary French university hospital. Pituitary apoplexy score was retrospectively applied in a perspective o...

ea0032p828 | Pituitary–Basic (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 pituitary adenomas, using immunohistochemical detection with specific MABs

Chinezu Laura , Vasiljevic Alexandre , Jouanneau Emmanuel , Francois Patrick , Borda Angela , Raverot Gerald , Trouillas Jacqueline

Background: Medical treatment of pituitary adenomas with somatostatin analogs depends on tumor type and somatostatin receptor expression. Using polyclonal antibodies, their immunohistochemical (IHC) detection gave conflicting results. Therefore, we studied the IHC expression of SSTR2A and SSTR5 using two specific MABs in five types of pituitary adenomas.Methods: SSTR2A and SSTR5 expression was studied using two...

ea0022p398 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Clinical, hormonal and molecular differences in pituitary ACTH adenomas without (silent corticotroph adenomas) or with Cushing's disease

Raverot Gerald , Wierinckx Anne , Jouanneau Emmanuel , Borson-Chazot Francoise , Lachuer Joel , Pugeat Michel , Trouillas Jacqueline

Objective: Silent corticotroph adenomas (SCA) are rare pituitary tumours immunoreactive for ACTH but without clinical evidence of Cushing’s disease. They have been compared to non functioning pituitary adenomas or ACTH adenomas with Cushing’s disease, but no distinction has been made between micro and macro ACTH-adenomas. We characterize SCA on clinical, hormonal and molecular data and compared the characteristic of these tumours with those of macro (MCA) and micro A...

ea0099p127 | Pituitary and Neuroendocrinology | ECE2024

Gonadotroph pituitary tumors: not always nonfunctioning

Carretti Anna , Diana Ilie Mirela , Vasiljevic Alexandre , Jaffrain-Rea Marie-Lise , Jouanneau Emmanuel , Raverot Gerald

Gonadotroph pituitary tumors (GnPiT) account for ~40% of pituitary tumors surgically treated and 70-75% of non-functional pituitary tumors. Functional gonadotropin-secreting tumors are rare and clinical manifestations vary according to the age and sex of the patient. They are benign tumors which, due to their silent nature, can grow and invade surrounding structures, making complete resection impossible and leading to recurrence in ~30% of cases.Objectiv...

ea0063gp101 | Adrenal and Neuroendocrine - Basic | ECE2019

Infiltrating CD68+/CD163+ macrophages regulate Gonadotroph-tumour invasion through collagen remodelling

Principe Moitza , Chanal Marie , Ilie Mirela D. , Vasiljevic Alexandre , Jouanneau Emmanuel , Hennino Ana , Raverot Gerald , Bertolino Philippe

Introduction: Pituitary Neuroendocrine tumours (PitNETs) present heterogenic characteristics based on their hormonal expression and secretion. While most PitNETs have a slow progression rate, a subset of them exhibit an aggressive behaviour with recurrence properties despite current surgery, radio- and chemotherapy. To explore new clinical strategies based on immunotherapy we initiated a systemic cartography of the pituitary tumour immune microenvironment (PiTME).<p class=...

ea0063p713 | Pituitary and Neuroendocrinology 2 | ECE2019

Characterizing the microenvironment of pituitary neuroendocrine tumours, new approaches and tools to explore the function and contribution of folliculostellate cells

Ilie Mirela Diana , Chanal Marie , Principe Moitza , Gadot Nicolas , Vasiljevic Alexandre , Jouanneau Emmanuel , Raverot Gerald , Bertolino Philippe

Background: Tumour microenvironment (TME) can comprise >50% of the tumour mass and includes non-tumour cells like immune cells and fibroblasts, as well as extracellular matrix, signaling molecules, and blood and lymph vessels. In recent years, TME has begun to be considered both a prognostic tool and a therapeutic target. While the existence of TME is well accepted and described in numerous cancers, little is known about the TME of pituitary neuroendocrine tumours (PitNETs...